Data updated: Jul 17, 2026
Dry Eye Clinical Trial Landscape
Dry Eye is being studied across 483 clinical trials registered since 2008, with 65 programs currently active. The competitive pipeline includes 10 active Phase 3 trials, 16 active Phase 2 trials, and 6 active Phase 1 trials.
, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd..
Trial activity
65 active / 483 total since 2008
Active by phase 10 Ph3 / 138 16 Ph2 / 149 6 Ph1 / 40 33 Ph4 / 156
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
AbbVie 2 20 3
Laboratorios Sophia S.A de C.V. 2 11 0
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 2 2 0
Bausch & Lomb Incorporated 1 12 1
Dompé Farmaceutici S.p.A 1 6 0
Huons Co., Ltd. 1 6 0
ORA, Inc. 1 3 1
BRIM Biotechnology Inc. 1 3 0
Laboratoires Thea 1 2 0
Oculis 1 1 0
Cambium Bio Limited 1 1 0
VivaVision Biotech, Inc 1 1 0
Azura Ophthalmics 1 1 0
Telios Pharma, Inc. 1 1 0
Rudacure 1 1 0
How the field has grown
New-trial starts peaked in 2021 (45 registered); 2025 saw 33. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (93 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 20
2017 17
2018 30
2019 35
2020 29
2021 45
2022 30
2023 29
2024 38
2025 33
2026 26
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (9) 180
2017 (2) 329
2018 (7) 209
2019 (12) 465
2020 (11) 329
2021 (14) 233
2022 (11) 275
2023 (7) 271
2024 (13) 297
2025 (4) 311
2026 (3) 160
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07529899 NOT YET RECRUITING
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft Versus Standard of Care in Participants With Moderate to Severe Dry Eye Disease
Cellution Biologics n=40
NCT07284381 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
AbbVie n=261
NCT06766357 RECRUITING
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=360
NCT06903611 NOT YET RECRUITING
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Cambium Bio Limited n=475
NCT06942793 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=396
NCT06931041 ACTIVE NOT RECRUITING
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial
Instituto de Oftalmología Fundación Conde de Valenciana n=25
NCT06879782 RECRUITING
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
Lunan Better Pharmaceutical Co., LTD. n=820
NCT06360133 RECRUITING
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
VivaVision Biotech, Inc n=700
NCT06329791 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
Azura Ophthalmics n=500
NCT04343287 COMPLETED
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
BRIM Biotechnology Inc. n=220
NCT04633213 COMPLETED
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
Harbour BioMed (Guangzhou) Co. Ltd. n=577
NCT06544694 COMPLETED
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Alcon Research n=80
NCT06660290 COMPLETED
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
Alcon Research n=55
NCT06388070 COMPLETED
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
Huons Co., Ltd. n=297
NCT05411367 COMPLETED
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
Seikagaku Corporation n=232
NCT06493604 COMPLETED
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=116
NCT07111013 WITHDRAWN
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Bausch & Lomb Incorporated
NCT05136170 COMPLETED
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Dompé Farmaceutici S.p.A n=85
NCT04735393 COMPLETED
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=757
NCT06717152 COMPLETED
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. n=427
NCT06424444 COMPLETED
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=421
NCT05493111 COMPLETED
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Aerie Pharmaceuticals n=275
NCT05360966 COMPLETED
Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Aerie Pharmaceuticals n=467
NCT05285644 COMPLETED
Study Evaluating the Safety and Efficacy of AR-15512
Aerie Pharmaceuticals n=465
NCT07050446 COMPLETED
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
Jadran Galenski laboratorij d.d. n=86
NCT06389214 COMPLETED
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=132
NCT06427031 COMPLETED
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Taejoon Pharmaceutical Co., Ltd. n=271
NCT04674358 COMPLETED
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=329
NCT05062330 COMPLETED
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=361
NCT03879863 COMPLETED
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=422
NCT05403827 COMPLETED
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
Kowa Research Institute, Inc. n=644
NCT04139798 COMPLETED
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Bausch & Lomb Incorporated n=599
NCT05201170 COMPLETED
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Palatin Technologies, Inc n=575
NCT05878067 COMPLETED
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
AbbVie n=40
NCT04144413 COMPLETED
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Santen SAS n=350
NCT04567329 COMPLETED
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Bausch & Lomb Incorporated n=620
NCT04181593 COMPLETED
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
OmegaD LLC n=322
NCT06517667 COMPLETED
Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye
University of Seville n=30
NCT05695781 COMPLETED
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
BRIM Biotechnology Inc. n=740
NCT06478134 COMPLETED
Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease
University of Seville n=124
NCT04393441 COMPLETED
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Allergan n=400
NCT05848128 COMPLETED
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc. n=642
NCT05133180 COMPLETED
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Dompé Farmaceutici S.p.A n=104
NCT06400589 SUSPENDED
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
HanAll BioPharma Co., Ltd. n=750
NCT06323395 COMPLETED
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
Jadran Galenski laboratorij d.d. n=64
NCT04140227 COMPLETED
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Bausch & Lomb Incorporated n=256
NCT04819269 COMPLETED
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Sylentis, S.A. n=203
NCT03920215 COMPLETED
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. n=101
NCT04683796 COMPLETED
Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease
Mahidol University n=96
NCT05109702 COMPLETED
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
HanAll BioPharma Co., Ltd. n=260
NCT04523142 COMPLETED
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
Novaliq GmbH n=202
NCT02205840 COMPLETED
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
Seikagaku Corporation n=240
NCT05082974 COMPLETED
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
Vance Thompson Vision ND n=40
NCT05841043 COMPLETED
Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease
Jiangsu HengRui Medicine Co., Ltd. n=206
NCT05378945 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Corxel Pharmaceuticals n=340
NCT03925727 COMPLETED
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc. n=623
NCT04899518 COMPLETED
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Allysta Pharmaceutical n=922
NCT04523129 COMPLETED
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Novaliq GmbH n=834
NCT05027087 COMPLETED
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
SightSage Foods and Nutrition Inc. n=68
NCT05322148 COMPLETED
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
Research Insight LLC n=59
NCT03292809 COMPLETED
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Novaliq GmbH n=328
NCT05598242 COMPLETED
Amniotic Membrane Treatment for Hyposecretory Dry Eye
Hospital Nacional Profesor Alejandro Posadas n=37
NCT02254265 COMPLETED
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Sun Pharmaceutical Industries Limited n=455
NCT05515471 COMPLETED
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
Jiangsu HengRui Medicine Co., Ltd. n=312
NCT03785340 COMPLETED
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
Ocugen n=252
NCT04670263 COMPLETED
Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)
Adom Advanced Optical Technologies Ltd. n=70
NCT05425914 COMPLETED
Impact of Vitamin D3 Supplementation in Non-Sjogren Dry Eye Patients With Low Serum Vitamin D Level
University of Faisalabad n=108
NCT03937882 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC n=700
NCT04541888 COMPLETED
Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=644
NCT03846453 COMPLETED
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
HanAll BioPharma Co., Ltd. n=637
NCT04206020 COMPLETED
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
Mitotech, SA n=610
NCT02974907 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC n=601
NCT04147650 COMPLETED
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. n=508
NCT04036292 COMPLETED
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. n=758
NCT05017844 COMPLETED
[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome
Kukje Pharma n=222
NCT02257957 COMPLETED
Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Universidad Nacional de Colombia n=30
NCT01743729 COMPLETED
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
Shire n=720
NCT02284516 COMPLETED
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
Shire n=711
NCT01421498 COMPLETED
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
Shire n=588
NCT04548427 COMPLETED
Study to Evaluate the Efficacy and Safety of CKD-352
Chong Kun Dang Pharmaceutical n=283
NCT01660256 COMPLETED
Confirmatory Study of OPC-12759 Ophthalmic Solution
Otsuka Pharmaceutical Co., Ltd. n=209
NCT02813265 COMPLETED
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Kala Pharmaceuticals, Inc. n=918
NCT04714099 COMPLETED
Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study
Alexandria University n=40
NCT02819284 COMPLETED
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Kala Pharmaceuticals, Inc. n=909
NCT01212471 COMPLETED
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
Bausch & Lomb Incorporated n=840
NCT02871440 COMPLETED
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
The University of New South Wales n=40
NCT03461575 COMPLETED
Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
Huons Co., Ltd. n=209
NCT01579539 COMPLETED
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
Medical University of Vienna n=18
NCT02980224 COMPLETED
Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
OmegaD LLC n=180
NCT02701764 COMPLETED
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
University of Miami n=43
NCT02597803 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
ReGenTree, LLC n=317
NCT01960010 COMPLETED
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc. n=403
NCT03518398 COMPLETED
Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction
Chulalongkorn University n=114
NCT03865888 COMPLETED
Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
Pavly Moawd n=60
NCT03527212 COMPLETED
A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease
Senju Pharmaceutical Co., Ltd. n=329
NCT01459588 COMPLETED
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
Allergan n=315
NCT01294384 COMPLETED
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
Allergan n=305
NCT02280473 COMPLETED
A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease
Allergan n=188
NCT02815293 TERMINATED
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Allergan n=36
NCT03108664 COMPLETED
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
Sylentis, S.A. n=330
NCT02965846 TERMINATED
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Allergan n=43
NCT01768312 COMPLETED
Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
Hanlim Pharm. Co., Ltd. n=84
NCT01657253 COMPLETED
Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
Laboratorios Sophia S.A de C.V. n=183
NCT02553772 COMPLETED
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
Allergan n=242
NCT02023268 COMPLETED
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Laboratoires Thea n=105
NCT02455050 COMPLETED
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
Allergan n=79
NCT02260960 COMPLETED
The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease
Physician Recommended Nutriceuticals n=122
NCT01568593 COMPLETED
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Laboratoires Thea n=93
NCT01664949 COMPLETED
A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease
Allergan n=460
NCT01804361 COMPLETED
Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes
DH Bio Co., Ltd. n=90
NCT02461719 COMPLETED
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
Taejoon Pharmaceutical Co., Ltd. n=158
NCT00831662 COMPLETED
The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)
Merck Sharp & Dohme LLC n=490
NCT00600288 COMPLETED
Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)
Merck Sharp & Dohme LLC n=261
NCT02051023 COMPLETED
Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA n=41
NCT01753596 WITHDRAWN
Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease
Medical University of Vienna
NCT02229955 COMPLETED
Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease
Hanlim Pharm. Co., Ltd. n=86
NCT01632137 COMPLETED
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
Kubota Vision Inc. n=564
NCT00818324 COMPLETED
Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Otsuka Pharmaceutical Co., Ltd. n=154
NCT00885079 COMPLETED
Confirmatory Study of OPC-12759 Ophthalmic Suspension
Otsuka Pharmaceutical Co., Ltd. n=188
NCT01339936 COMPLETED
Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
Optometric Technology Group Ltd n=40
NCT01601028 COMPLETED
Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
Seoul National University Hospital n=39
NCT01382225 COMPLETED
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Alcon Research n=1,936
NCT01202747 COMPLETED
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
TearScience, Inc. n=50
NCT01129856 COMPLETED
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
Eyegate Pharmaceuticals, Inc. n=198
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only